[
  {
    "title": "MAXLINEAR, INC.",
    "subtitle": "UNAUDITED GAAP CONSOLIDATED STATEMENTS OF OPERATIONS",
    "markdown": "| | Three Months Ended December 31, 2024 | Three Months Ended September 30, 2024 | Three Months Ended December 31, 2023 |\n| --- | --- | --- | --- |\n| Net revenue | $ 92,167 | $ 81,102 | $ 125,353 |\n| Cost of net revenue | 40,919 | 37,022 | 56,814 |\n| Gross profit | 51,248 | 44,080 | 68,539 |\n| Operating expenses: | | | |\n| Research and development | 51,278 | 52,604 | 65,250 |\n| Selling, general and administrative | 38,087 | 30,154 | 34,384 |\n| Impairment losses | | 1,237 | |\n| Restructuring charges | 3,056 | 26,828 | 10,648 |\n| Total operating expenses | 92,421 | 110,823 | 110,282 |\n| Loss from operations | (41,173) | (66,743) | (41,743) |\n| Interest income | 1,040 | 1,653 | 1,781 |\n| Interest expense | (2,802) | (2,655) | (2,909) |\n| Other income (expense), net | 2,113 | (14,753) | 240 |\n| Total other income (expense), net | 351 | (15,755) | (888) |\n| Loss before income taxes | (40,822) | (82,498) | (42,631) |\n| Income tax provision (benefit) | 17,016 | (6,713) | (4,131) |\n| Net loss | $ (57,838) | $ (75,785) | $ (38,500) |\n| Net loss per share: | | | |\n| Basic | $ (0.68) | $ (0.90) | $ (0.47) |\n| Diluted | $ (0.68) | $ (0.90) | $ (0.47) |\n| Shares used to compute net loss per share: | | | |\n| Basic | 84,485 | 84,074 | 81,681 |\n| Diluted | 84,485 | 84,074 | 81,681 |",
    "footnotes": [],
    "units": "(in thousands, except per share data)",
    "page": 8,
    "bbox": [
      23.5,
      348.8,
      586.3,
      755.9
    ],
    "som_region": [
      0.03839231004901961,
      0.04556956435694839,
      0.9580457101460376,
      0.5595486573498658
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/113264601/113264601.pdf",
    "camelot_accuracy": 97.53,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "MAXLINEAR, INC.",
    "subtitle": "UNAUDITED GAAP CONSOLIDATED STATEMENTS OF OPERATIONS",
    "markdown": "| | Twelve Months Ended December 31, 2024 | Twelve Months Ended December 31, 2023 |\n| --- | --- | --- |\n| Net revenue | $ 360,528 | $ 693,263 |\n| Cost of net revenue | 165,746 | 307,600 |\n| Gross profit | 194,782 | 385,663 |\n| Operating expenses: | | |\n| Research and development | 225,189 | 269,504 |\n| Selling, general and administrative | 138,329 | 132,156 |\n| Impairment losses | 1,237 | 2,438 |\n| Restructuring charges | 53,379 | 19,786 |\n| Total operating expenses | 418,134 | 423,884 |\n| Loss from operations | (223,352) | (38,221) |\n| Interest income | 6,386 | 6,053 |\n| Interest expense | (10,874) | (10,702) |\n| Other income (expense), net | (10,877) | (20,940) |\n| Total other income (expense), net | (15,365) | (25,589) |\n| Loss before income taxes | (238,717) | (63,810) |\n| Income tax provision | 6,481 | 9,337 |\n| Net loss | $ (245,198) | $ (73,147) |\n| Net loss per share: | | |\n| Basic | $ (2.93) | $ (0.91) |\n| Diluted | $ (2.93) | $ (0.91) |\n| Shares used to compute net loss per share: | | |\n| Basic | 83,600 | 80,719 |\n| Diluted | 83,600 | 80,719 |",
    "footnotes": [],
    "units": "(in thousands, except per share data)",
    "page": 9,
    "bbox": [
      23.5,
      338.3,
      588.0,
      755.9
    ],
    "som_region": [
      0.03839231004901961,
      0.04556956435694839,
      0.9607198877272263,
      0.5728062331074416
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/113264601/113264601.pdf",
    "camelot_accuracy": 97.13,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "MAXLINEAR, INC.",
    "subtitle": "UNAUDITED GAAP CONSOLIDATED STATEMENTS OF CASH FLOWS",
    "markdown": "| | Three Months Ended December 31, 2024 | Three Months Ended September 30, 2024 | Three Months Ended December 31, 2023 |\n| --- | --- | --- | --- |\n| Operating Activities | | | |\n| Net loss | $ (57,838) | $ (75,785) | $ (38,500) |\n| Adjustments to reconcile net loss to net cash used in operating activities: | | | |\n| Amortization and depreciation | 11,714 | 12,142 | 16,593 |\n| Impairment of intangible assets | | 1,237 | |\n| Impairment of investments and other assets | | 14,000 | |\n| Amortization of debt issuance costs and accretion of discount on debt and leases | 548 | 637 | 703 |\n| Stock-based compensation | 18,813 | 12,788 | 16,413 |\n| Deferred income taxes | 13,884 | (8,320) | (10,954) |\n| Loss on disposal of property and equipment | | 623 | |\n| Gain on sale of investments | | | (434) |\n| Unrealized holding gain on investments | | | (2,152) |\n| Impairment of leased right-of-use assets | 2,140 | 677 | |\n| Gain on extinguishment of lease liabilities | (1) | (1) | |\n| (Gain) loss on foreign currency and other | (2,226) | 2,339 | 2,335 |\n| Excess tax deficiencies on stock based awards | 262 | 1,469 | 276 |\n| Changes in operating assets and liabilities: | | | |\n| Accounts receivable, net | (37,534) | 37,010 | (12,363) |\n| Inventory | 5,720 | (1,325) | 15,034 |\n| Prepaid expenses and other assets | 6,742 | (7,852) | 887 |\n| Accounts payable, accrued expenses and other current liabilities | 17,448 | (6,708) | (11,514) |\n| Accrued compensation | (2,092) | 159 | 932 |\n| Accrued price protection liability | (1,071) | (17,158) | 3,474 |\n| Lease liabilities | (2,889) | (2,761) | (2,780) |\n| Other long-term liabilities | (1,458) | 6,098 | 5,477 |\n| Net cash used in operating activities | (27,838) | (30,731) | (16,573) |\n| Investing Activities | | | |\n| Purchases of property and equipment | (2,193) | (4,132) | (1,274) |\n| Purchases of intangible assets | (805) | (1,818) | (157) |\n| Cash used in acquisitions, net of cash acquired | | | (940) |\n| Sales of trading securities | | | 17,198 |\n| Net cash provided by (used in) investing activities | (2,998) | (5,950) | 14,827 |\n| Financing Activities | | | |\n| Net proceeds from issuance of common stock | 2,512 | | 1,391 |\n| Minimum tax withholding paid on behalf of employees for restricted stock units | (1,091) | (58) | (220) |\n| Net cash provided by (used in) financing activities | 1,421 | (58) | 1,171 |\n| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (474) | 94 | 779 |\n| Increase (decrease) in cash, cash equivalents and restricted cash | (29,889) | (36,645) | 204 |\n| Cash, cash equivalents and restricted cash at beginning of period | 149,492 | 186,137 | 188,152 |\n| Cash, cash equivalents and restricted cash at end of period | $ 119,603 | $ 149,492 | $ 188,356 |",
    "footnotes": [],
    "units": "(in thousands)",
    "page": 10,
    "bbox": [
      23.5,
      108.8,
      588.0,
      755.9
    ],
    "som_region": [
      0.03839231004901961,
      0.04556956435694839,
      0.9607241761450673,
      0.8625789603801689
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/113264601/113264601.pdf",
    "camelot_accuracy": 97.44,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "MAXLINEAR, INC.",
    "subtitle": "UNAUDITED GAAP CONSOLIDATED STATEMENTS OF CASH FLOWS",
    "markdown": "| | Year Ended December 31, 2024 | Year Ended December 31, 2023 |\n| --- | --- | --- |\n| Operating Activities | | |\n| Net loss | $ (245,198) | $ (73,147) |\n| Adjustments to reconcile net loss to cash provided by (used in) operating activities: | | |\n| Amortization and depreciation | 54,140 | 71,516 |\n| Impairment of intangible assets | 1,237 | 2,438 |\n| Impairment of investments and other assets | 14,000 | |\n| Amortization of debt issuance costs and accretion of discount on debt and leases | 2,538 | 2,561 |\n| Stock-based compensation | 66,021 | 55,176 |\n| Deferred income taxes | 826 | (4,452) |\n| Loss on disposal of property and equipment | 1,068 | 2,057 |\n| Gain on sale of investments | | (434) |\n| Unrealized holding loss on investments | | 1,765 |\n| Impairment of leased right-of-use assets | 5,555 | |\n| Gain on settlement of pension | | (1,008) |\n| Gain on extinguishment of lease liabilities | (555) | |\n| (Gain) loss on foreign currency | (1,253) | 2,475 |\n| Excess tax (benefits) deficiencies on stock based awards | 3,250 | (253) |\n| Changes in operating assets and liabilities: | | |\n| Accounts receivable, net | 85,155 | 1,406 |\n| Inventory | 9,565 | 60,636 |\n| Prepaid expenses and other assets | (1,873) | (9,328) |\n| Accounts payable, accrued expenses and other current liabilities | (4,569) | (29,431) |\n| Accrued compensation | 919 | 9,708 |\n| Accrued price protection liability | (28,283) | (41,562) |\n| Lease liabilities | (10,695) | (11,671) |\n| Other long-term liabilities | 2,857 | 4,920 |\n| Net cash provided by (used in) operating activities | (45,295) | 43,372 |\n| Investing Activities | | |\n| Purchases of property and equipment | (17,680) | (13,454) |\n| Purchases of intangible assets | (5,766) | (6,355) |\n| Cash used in acquisitions, net of cash acquired | | (13,324) |\n| Sales of trading securities | | 17,198 |\n| Net cash used in investing activities | (23,446) | (15,935) |\n| Financing Activities | | |\n| Payment of debt commitment fees | | (18,325) |\n| Net proceeds from issuance of common stock | 4,091 | 4,559 |\n| Minimum tax withholding paid on behalf of employees for restricted stock units | (2,805) | (12,590) |\n| Net cash provided by (used in) financing activities | 1,286 | (26,356) |\n| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (1,298) | (1,082) |\n| Decrease in cash, cash equivalents and restricted cash | (68,753) | (1) |\n| Cash, cash equivalents and restricted cash at beginning of period | 188,356 | 188,357 |\n| Cash, cash equivalents and restricted cash at end of period | $ 119,603 | $ 188,356 |",
    "footnotes": [],
    "units": "(in thousands)",
    "page": 12,
    "bbox": [
      23.5,
      73.6,
      588.0,
      755.9
    ],
    "som_region": [
      0.03839231004901961,
      0.04556956435694839,
      0.960743324429381,
      0.9070865361377446
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/113264601/113264601.pdf",
    "camelot_accuracy": 98.37,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "MAXLINEAR, INC.",
    "subtitle": "UNAUDITED GAAP CONDENSED CONSOLIDATED BALANCE SHEETS",
    "markdown": "|  | December 31, 2024 | September 30, 2024 | December 31, 2023 |\n| --- | --- | --- | --- |\n| Assets |  |  |  |\n| Current assets: |  |  |  |\n| Cash and cash equivalents | $ 118,575 | $ 148,476 | $ 187,288 |\n| Short-term restricted cash | 1,003 | 993 | 1,051 |\n| Accounts receivable, net | 85,464 | 47,930 | 170,619 |\n| Inventory | 90,343 | 96,063 | 99,908 |\n| Prepaid expenses and other current assets | 28,057 | 34,798 | 29,159 |\n| Total current assets | 323,442 | 328,260 | 488,025 |\n| Long-term restricted cash | 25 | 23 | 17 |\n| Property and equipment, net | 59,300 | 63,493 | 66,431 |\n| Leased right-of-use assets | 18,184 | 22,549 | 31,264 |\n| Intangible assets, net | 55,008 | 58,031 | 73,630 |\n| Goodwill | 318,588 | 318,588 | 318,588 |\n| Deferred tax assets | 68,662 | 82,552 | 69,493 |\n| Other long-term assets | 21,430 | 21,807 | 32,809 |\n| Total assets | $ 864,639 | $ 895,303 | $ 1,080,257 |\n| Liabilities and stockholders equity |  |  |  |\n| Current liabilities | $ 182,284 | $ 168,597 | $ 222,129 |\n| Long-term lease liabilities | 16,952 | 19,433 | 26,243 |\n| Long-term debt | 122,996 | 122,840 | 122,375 |\n| Other long-term liabilities | 26,124 | 27,561 | 23,245 |\n| Stockholders equity | 516,283 | 556,872 | 686,265 |\n| Total liabilities and stockholders equity | $ 864,639 | $ 895,303 | $ 1,080,257 |",
    "footnotes": [],
    "units": "(in thousands)",
    "page": 14,
    "bbox": [
      23.5,
      355.6,
      586.3,
      755.9
    ],
    "som_region": [
      0.03839231004901961,
      0.04556956435694839,
      0.9580582762076184,
      0.5510259300771385
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/113264601/113264601.pdf",
    "camelot_accuracy": 98.18,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "Three Months Ended",
    "subtitle": "",
    "markdown": "| | December 31, 2024 | September 30, 2024 | December 31, 2023 |\n| --- | --- | --- | --- |\n| GAAP gross profit | $ 51,248 | $ 44,080 | $ 68,539 |\n| Stock-based compensation | 186 | 81 | 137 |\n| Performance based equity | 8 | (19) | 17 |\n| Amortization of purchased intangible assets | 2,990 | 3,498 | 8,332 |\n| Non-GAAP gross profit | 54,432 | 47,640 | 77,025 |\n| GAAP R&D expenses | 51,278 | 52,604 | 65,250 |\n| Stock-based compensation | (10,862) | (7,423) | (11,061) |\n| Performance based equity | (743) | 775 | (1,918) |\n| Research and development funded by others | | 3,000 | (2,000) |\n| Non-GAAP R&D expenses | 39,673 | 48,956 | 50,271 |\n| GAAP SG&A expenses | 38,087 | 30,154 | 34,384 |\n| Stock-based compensation | (7,766) | (5,284) | (5,215) |\n| Performance based equity | (811) | 384 | (1,324) |\n| Amortization of purchased intangible assets | (592) | (591) | (591) |\n| Acquisition and integration costs | (7,261) | (801) | (1,799) |\n| Non-GAAP SG&A expenses | 21,657 | 23,862 | 25,455 |\n| GAAP impairment losses | | 1,237 | |\n| Impairment losses | | (1,237) | |\n| Non-GAAP impairment losses | | | |\n| GAAP restructuring expenses | 3,056 | 26,828 | 10,648 |\n| Restructuring charges | (3,056) | (26,828) | (10,648) |\n| Non-GAAP restructuring expenses | | | |\n| GAAP loss from operations | (41,173) | (66,743) | (41,743) |\n| Total non-GAAP adjustments | 34,275 | 41,565 | 43,042 |\n| Non-GAAP income (loss) from operations | (6,898) | (25,178) | 1,299 |\n| GAAP interest and other income (expense), net | 351 | (15,755) | (888) |\n| Non-recurring interest and other income (expense), net | 326 | 11,769 | 54 |\n| Non-GAAP interest and other income (expense), net | 677 | (3,986) | (834) |\n| GAAP loss before income taxes | (40,822) | (82,498) | (42,631) |\n| Total non-GAAP adjustments | 34,601 | 53,334 | 43,096 |\n| Non-GAAP income (loss) before income taxes | (6,221) | (29,164) | 465 |\n| GAAP income tax provision (benefit) | 17,016 | (6,713) | (4,131) |\n| Adjustment for non-cash tax benefits/expenses | (16,016) | 7,568 | 4,177 |\n| Non-GAAP income tax provision | 1,000 | 855 | 46 |\n| GAAP net loss | (57,838) | (75,785) | (38,500) |\n| Total non-GAAP adjustments before income taxes | 34,601 | 53,334 | 43,096 |\n| Less: total tax adjustments | (16,016) | 7,568 | 4,177 |\n| Non-GAAP net income (loss) | $ (7,221) | $ (30,019) | $ 419 |\n| Shares used in computing GAAP and non-GAAP basic net income (loss) per share | 84,485 | 84,074 | 81,681 |\n| Shares used in computing GAAP diluted net loss per share | 84,485 | 84,074 | 81,681 |\n| Dilutive common stock equivalents | | | 1,000 |\n| Shares used in computing non-GAAP diluted net income (loss) per share | 84,485 | 84,074 | 82,681 |\n| Non-GAAP basic net income (loss) per share | $ (0.09) | $ (0.36) | $ 0.01 |\n| Non-GAAP diluted net income (loss) per share | $ (0.09) | $ (0.36) | $ 0.01 |",
    "footnotes": [],
    "units": "",
    "page": 16,
    "bbox": [
      23.5,
      78.3,
      587.9,
      767.6
    ],
    "som_region": [
      0.03839231004901961,
      0.030777208732836174,
      0.960650275735294,
      0.901132294625947
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/113264601/113264601.pdf",
    "camelot_accuracy": 99.33,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "Year ended",
    "subtitle": "",
    "markdown": "| | December 31, 2024 | December 31, 2023 |\n| --- | --- | --- |\n| GAAP gross profit | $ 194,782 | $ 385,663 |\n| Stock-based compensation | 621 | 763 |\n| Performance based equity | 24 | 111 |\n| Amortization of purchased intangible assets | 19,798 | 35,102 |\n| Non-GAAP gross profit | 215,225 | 421,639 |\n| GAAP R&D expenses | 225,189 | 269,504 |\n| Stock-based compensation | (38,814) | (44,189) |\n| Performance based equity | (3,108) | (7,568) |\n| Research and development funded by others | 2,000 | (9,500) |\n| Non-GAAP R&D expenses | 185,267 | 208,247 |\n| GAAP SG&A expenses | 138,329 | 132,156 |\n| Stock-based compensation | (26,586) | (10,224) |\n| Performance based equity | (2,132) | (3,874) |\n| Amortization of purchased intangible assets | (2,366) | (2,881) |\n| Acquisition and integration costs | (8,828) | (9,286) |\n| Non-GAAP SG&A expenses | 98,417 | 105,891 |\n| GAAP impairment losses | 1,237 | 2,438 |\n| Impairment losses | (1,237) | (2,438) |\n| Non-GAAP impairment losses | | |\n| GAAP restructuring expenses | 53,379 | 19,786 |\n| Restructuring charges | (53,379) | (19,786) |\n| Non-GAAP restructuring expenses | | |\n| GAAP loss from operations | (223,352) | (38,221) |\n| Total non-GAAP adjustments | 154,893 | 145,722 |\n| Non-GAAP income (loss) from operations | (68,459) | 107,501 |\n| GAAP interest and other income (expense), net | (15,365) | (25,589) |\n| Non-recurring interest and other income (expense), net | 12,233 | 18,628 |\n| Non-GAAP interest and other income (expense), net | (3,132) | (6,961) |\n| GAAP loss before income taxes | (238,717) | (63,810) |\n| Total non-GAAP adjustments | 167,126 | 164,350 |\n| Non-GAAP income (loss) before income taxes | (71,591) | 100,540 |\n| GAAP income tax provision | 6,481 | 9,337 |\n| Adjustment for non-cash tax benefits/expenses | (2,481) | 717 |\n| Non-GAAP income tax provision | 4,000 | 10,054 |\n| GAAP net loss | (245,198) | (73,147) |\n| Total non-GAAP adjustments before income taxes | 167,126 | 164,350 |\n| Less: total tax adjustments | (2,481) | 717 |\n| Non-GAAP net income (loss) | $ (75,591) | $ 90,486 |\n| Shares used in computing GAAP and non-GAAP basic net income (loss) per share | 83,600 | 80,719 |\n| Shares used in computing GAAP diluted net loss per share | 83,600 | 80,719 |\n| Dilutive common stock equivalents | | 1,210 |\n| Shares used in computing non-GAAP diluted net income (loss) per share | 83,600 | 81,929 |\n| Non-GAAP basic net income (loss) per share | $ (0.90) | $ 1.12 |\n| Non-GAAP diluted net income (loss) per share | $ (0.90) | $ 1.10 |",
    "footnotes": [],
    "units": "",
    "page": 19,
    "bbox": [
      23.5,
      87.3,
      582.0,
      752.6
    ],
    "som_region": [
      0.03839231004901961,
      0.04971660267223011,
      0.9509420955882353,
      0.8897686582623106
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/113264601/113264601.pdf",
    "camelot_accuracy": 99.24,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "MAXLINEAR, INC.",
    "subtitle": "UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES AS A PERCENTAGE OF NET REVENUE",
    "markdown": "| | Three Months Ended December 31, 2024 | Three Months Ended September 30, 2024 | Three Months Ended December 31, 2023 |\n| --- | --- | --- | --- |\n| GAAP gross margin | 55.6% | 54.4% | 54.7% |\n| Stock-based compensation | 0.2% | 0.1% | 0.1% |\n| Performance based equity | % | % | % |\n| Amortization of purchased intangible assets | 3.2% | 4.3% | 6.7% |\n| Non-GAAP gross margin | 59.1% | 58.7% | 61.4% |\n| GAAP R&D expenses | 55.6% | 64.9% | 52.1% |\n| Stock-based compensation | (11.8)% | (9.2)% | (8.8)% |\n| Performance based equity | (0.8)% | 1.0% | (1.5)% |\n| Research and development funded by others | % | 3.7% | (1.6)% |\n| Non-GAAP R&D expenses | 43.0% | 60.4% | 40.1% |\n| GAAP SG&A expenses | 41.3% | 37.2% | 27.4% |\n| Stock-based compensation | (8.4)% | (6.5)% | (4.2)% |\n| Performance based equity | (0.9)% | 0.5% | (1.1)% |\n| Amortization of purchased intangible assets | (0.6)% | (0.7)% | (0.5)% |\n| Acquisition and integration costs | (7.9)% | (1.0)% | (1.4)% |\n| Non-GAAP SG&A expenses | 23.5% | 29.4% | 20.3% |\n| GAAP impairment losses | % | 1.5% | % |\n| Impairment losses | % | (1.5)% | % |\n| Non-GAAP impairment losses | % | % | % |\n| GAAP restructuring expenses | 3.3% | 33.1% | 8.5% |\n| Restructuring charges | (3.3)% | (33.1)% | (8.5)% |\n| Non-GAAP restructuring expenses | % | % | % |\n| GAAP loss from operations | (44.7)% | (82.3)% | (33.3)% |\n| Total non-GAAP adjustments | 37.2% | 51.3% | 34.3% |\n| Non-GAAP income (loss) from operations | (7.5)% | (31.0)% | 1.0% |\n| GAAP interest and other income (expense), net | 0.4% | (19.4)% | (0.7)% |\n| Non-recurring interest and other income (expense), net | 0.4% | 14.5% | % |\n| Non-GAAP interest and other income (expense), net | 0.7% | (4.9)% | (0.7)% |\n| GAAP loss before income taxes | (44.3)% | (101.7)% | (34.0)% |\n| Total non-GAAP adjustments before income taxes | 37.5% | 65.8% | 34.4% |\n| Non-GAAP income (loss) before income taxes | (6.8)% | (36.0)% | 0.4% |\n| GAAP income tax provision (benefit) | 18.5% | (8.3)% | (3.3)% |\n| Adjustment for non-cash tax benefits/expenses | (17.4)% | 9.3% | 3.3% |\n| Non-GAAP income tax provision | 1.1% | 1.1% | % |\n| GAAP net loss | (62.8)% | (93.4)% | (30.7)% |\n| Total non-GAAP adjustments before income taxes | 37.5% | 65.8% | 34.4% |\n| Less: total tax adjustments | (17.4)% | 9.3% | 3.3% |\n| Non-GAAP net income (loss) | (7.8)% | (37.0)% | 0.3% |",
    "footnotes": [],
    "units": "",
    "page": 21,
    "bbox": [
      23.5,
      123.3,
      586.9,
      755.9
    ],
    "som_region": [
      0.03839231004901961,
      0.04556956435694839,
      0.9589411916296466,
      0.8443141128077651
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/113264601/113264601.pdf",
    "camelot_accuracy": 98.7,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "MAXLINEAR, INC.",
    "subtitle": "UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES AS A PERCENTAGE OF NET REVENUE",
    "markdown": "| | Year ended December 31, 2024 | Year ended December 31, 2023 |\n| --- | --- | --- |\n| GAAP gross margin | 54.0% | 55.6% |\n| Stock-based compensation | 0.2% | 0.1% |\n| Performance based equity | % | % |\n| Amortization of purchased intangible assets | 5.5% | 5.1% |\n| Non-GAAP gross margin | 59.7% | 60.8% |\n| GAAP R&D expenses | 62.5% | 38.9% |\n| Stock-based compensation | (10.8)% | (6.4)% |\n| Performance based equity | (0.9)% | (1.1)% |\n| Research and development funded by others | 0.6% | (1.4)% |\n| Non-GAAP R&D expenses | 51.4% | 30.0% |\n| GAAP SG&A expenses | 38.4% | 19.1% |\n| Stock-based compensation | (7.4)% | (1.5)% |\n| Performance based equity | (0.6)% | (0.6)% |\n| Amortization of purchased intangible assets | (0.7)% | (0.4)% |\n| Acquisition and integration costs | (2.5)% | (1.3)% |\n| Non-GAAP SG&A expenses | 27.3% | 15.3% |\n| GAAP impairment losses | 0.3% | 0.4% |\n| Impairment losses | (0.3)% | (0.4)% |\n| Non-GAAP impairment losses | % | % |\n| GAAP restructuring expenses | 14.8% | 2.9% |\n| Restructuring charges | (14.8)% | (2.9)% |\n| Non-GAAP restructuring expenses | % | % |\n| GAAP loss from operations | (62.0)% | (5.5)% |\n| Total non-GAAP adjustments | 43.0% | 21.0% |\n| Non-GAAP income (loss) from operations | (19.0)% | 15.5% |\n| GAAP interest and other income (expense), net | (4.3)% | (3.7)% |\n| Non-recurring interest and other income (expense), net | 3.4% | 2.7% |\n| Non-GAAP interest and other income (expense), net | (0.9)% | (1.0)% |\n| GAAP loss before income taxes | (66.2)% | (9.2)% |\n| Total non-GAAP adjustments | 46.4% | 23.7% |\n| Non-GAAP income (loss) before income taxes | (19.9)% | 14.5% |\n| GAAP income tax provision | 1.8% | 1.4% |\n| Adjustment for non-cash tax benefits/expenses | (0.7)% | 0.1% |\n| Non-GAAP income tax provision | 1.1% | 1.5% |\n| GAAP net loss | (68.0)% | (10.6)% |\n| Total non-GAAP adjustments before income taxes | 46.4% | 23.7% |\n| Less: total tax adjustments | (0.7)% | 0.1% |\n| Non-GAAP net income (loss) | (21.0)% | 13.1% |",
    "footnotes": [],
    "units": "",
    "page": 22,
    "bbox": [
      23.5,
      115.1,
      583.4,
      755.9
    ],
    "som_region": [
      0.03839231004901961,
      0.04556956435694839,
      0.9532350029041564,
      0.8547307794744318
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/113264601/113264601.pdf",
    "camelot_accuracy": 99.17,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  }
]